Researchers at the University of Arizona Cancer Center discovered a new class of iron-targeting compounds that hamper the proliferation of cultured malignant cells in a laboratory setting.
The results of the study were published in the Journal of the American Chemical Society.
“Cancer cells are what we call ‘addicted’ to iron, and so we are making compounds that are able to interfere with the availability of iron in cancer cells,” said Elisa Tomat, PhD, professor in the Department of Chemistry and Biochemistry at the UArizona College of Science and member of the UArizona Cancer Center.
The discovery could lead to the development of broad-spectrum, anticancer drugs that target iron metabolism.
Iron is the most abundant transition metal in the human body and, according to Tomat, plays a crucial role in tumour progression and metastasis.
Cancer cells rely on several iron-dependent processes to sustain their rapid proliferation rates and therefore have a higher demand for this element compared with normal cells.
Tomat said the research team’s challenge was capturing iron within malignant cells yet keeping it available to the rest of the body.
To do so, they targeted intracellular iron with compounds that are activated only after cellular uptake.
“As chemists, we can design and synthesise molecules that are able to bind iron only under certain conditions and not throughout the body,” Tomat said.
“We've been working on various approaches toward this type of chemistry; we call these prochelator approaches because the chelator is the compound that binds the metal ion. The prochelator is the compound we designed to become activated only upon undergoing a certain reaction that occurs in cells.”
The research was inspired by a “common reagent,” a compound that is employed in laboratories worldwide to assess the ability of drug candidates to inhibit the proliferation of cultured mammalian cells.
“Because iron is such a fundamental player that is important in many cancer types, and this high demand for iron is a general characteristic of malignancy, I've been interested in this strategy for a number of years,” said Tomat, who has been exploring iron chelators and their role in tumour progression for more than 10 years.
“We're excited about this new strategy because we think this class of molecules can be further modified to optimise the properties and improve the antiproliferative activity and really become a way for us to impact the iron availability in malignant cells and halt cancer growth.”
Tomat’s co-authors include former postdoctoral associate Zoufeng Xu, PhD, and doctoral student Yu-Shien Sung.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.